Seragon Biosciences has unveiled promising preclinical results for SRN-901, an oral combinatorial longevity drug, demonstrating significant physiological benefits and lifespan extension in aged mice. In a study published in Drug Design, Development and Therapy, 18-month-old C57BL/6 mice on a Western diet exhibited a 33% increase in median remaining lifespan compared to the placebo group. The analysis revealed a 46% reduction in the hazard of death according to Cox proportional hazards modeling, positioning SRN-901 as a potent contender in the longevity therapeutics landscape.

The findings underscore the potential clinical impact of SRN-901, as it not only enhances lifespan but also significantly mitigates frailty progression by 70% and reduces tumor incidence by 30.53% in treated mice. Multi-omics profiling indicated that SRN-901 treatment led to the upregulation of DNA repair mechanisms and pathways associated with cellular repair, energy metabolism, and stress resistance, while concurrently downregulating apoptosis, inflammatory responses, and mTORC1 signaling. These comprehensive changes suggest a robust mechanism of action that could translate into improved healthspan alongside lifespan extension.

The implications of this research are substantial, particularly in shifting the paradigm of longevity drug development towards multi-target interventions. By combining longevity-associated compounds with SRN-820, SRN-901 exemplifies a novel approach that may accelerate the translation of preclinical findings into clinical applications. This strategy could redefine therapeutic timelines and enhance the efficacy of longevity treatments, making it a focal point for future research and development in the field of aging biology.

Source: longevity.technology